Belite Bio, Inc. 已正式完成向美国食品药品监督管理局（FDA）滚动提交其候选药物Tinlarebant的新药申请（NDA），该药物旨在治疗1型Stargardt病。此次滚动提交的完成标志着该药物在寻求监管批准以应对这一罕见眼科疾病的道路上迈出了关键一步。
Belite Bio, Inc. 已正式完成向美国食品药品监督管理局（FDA）滚动提交其候选药物Tinlarebant的新药申请（NDA），该药物旨在治疗1型Stargardt病。此次滚动提交的完成标志着该药物在寻求监管批准以应对这一罕见眼科疾病的道路上迈出了关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.